Advances in Cell Therapy for Liver Disease

2012 ◽  
pp. 138-153
Author(s):  
Luke Boulter
Keyword(s):  
Liver Disease ◽  
Cell Therapy

Allogeneic Cell Therapy for the Treatment of Liver Disease

2005 ◽  
Vol 15 (2) ◽  
pp. 178-184
Author(s):  
John W. Ludlow ◽  
Andrew T. Bruce ◽  
Michael J. Kulik ◽  
Sonya O. Meheux ◽  
Darell W. McCoy ◽  
...  
Keyword(s):  
Liver Disease ◽  
Cell Therapy ◽  
Severe Liver ◽  
Human Organs ◽  
Allogeneic Cell Therapy ◽  
Cryopreserved Cell ◽  
Liver Functions ◽  
Severe Liver Disease ◽  
Liver Replacement ◽  
Organ Replacement

The scarcity of human organs available for transplantation is clearly evident. Efforts to maximize the use of available organs and to increase the number of donors have increased the number of transplantations performed, but at a rate that remains far behind the rate of growth of the waiting list. Thus, the likelihood of a patient with severe liver disease receiving a liver replacement is decreasing. In order to offer treatment to most patients with liver disease, alternatives to whole-organ replacement must be found. Cell-based treatments, in which suspensions of liver cells are injected into patients with liver failure and reconstitute the patient's liver functions, may be that alternative. Here, we report on a regulatory-compliant process for the production of a cryopreserved cell therapy product that yields viable, metabolically active hepatocytes that can be infused directly into patients with the goal of reconstituting liver function.

scholarly journals Therapeutic effect and safety of stem cell therapy for chronic liver disease: a systematic review and meta-analysis of randomized controlled trials

2020 ◽  
Vol 11 (1) ◽  
Author(s):  
Guang-Peng Zhou ◽  
Yi-Zhou Jiang ◽  
Li-Ying Sun ◽  
Zhi-Jun Zhu
Keyword(s):  
Stem Cell ◽  
Liver Disease ◽  
Adverse Events ◽  
Cell Therapy ◽  
Stem Cell Therapy ◽  
Meta Analysis ◽  
Chronic Liver ◽  
Controlled Trials ◽  
Therapeutic Effects ◽  
Term Survival

Abstract Background Stem cell therapy is becoming an emerging therapeutic option for chronic liver disease (CLD). However, whether stem cell therapy is more effective than conventional treatment remains questionable. We performed a large-scale meta-analysis of randomized controlled trials (RCTs) to evaluate the therapeutic effects and safety of stem cell therapy for CLD. Methods We systematically searched MEDLINE, EMBASE, the Cochrane Central Register of Controlled Trials (CENTRAL), and ClinicalTrials.gov databases for the period from inception through March 16, 2020. Primary outcomes were all-cause mortality and adverse events related to stem cell therapy. Secondary outcomes included the model for end-stage liver disease score, total bilirubin, albumin, alanine aminotransferase, prothrombin activity, and international normalized ratio. The standardized mean difference (SMD) and odds ratio (OR) with 95% confidence interval (CI) were calculated using a random-effects model. Results Twenty-four RCTs were included and the majority of these studies showed a high risk of bias. The meta-analysis indicated that compared with conventional treatment, stem cell therapy was associated with improved survival and liver function including the model of end-stage liver disease score, total bilirubin, and albumin levels. However, it had no obvious beneficial effects on alanine aminotransferase level, prothrombin activity, and international normalized ratio. Subgroup analyses showed stem cell therapy conferred a short-term survival benefit for patients with acute-on-chronic liver failure (ACLF), a single injection was more effective than multiple injections, hepatic arterial infusion was more effective than intravenous infusion, and bone marrow-derived stem cells were more effective than those derived from the umbilical cord. Thirteen trials reported adverse events related to stem cell therapy, but no serious adverse events were reported. Conclusions Stem cell therapy is a safe and effective therapeutic option for CLD, while patients with ACLF benefit the most in terms of improved short-term survival. A single injection administration of bone marrow-derived stem cells via the hepatic artery has superior therapeutic effects.

Hepatocyte cell therapy in liver disease

2015 ◽  
Vol 9 (10) ◽  
pp. 1261-1272 ◽  
Author(s):  
David Christopher Bartlett ◽  
Philip N Newsome
Keyword(s):  
Liver Disease ◽  
Cell Therapy

Molecular mechanisms of stem cell therapy in alcoholic liver disease

2014 ◽  
Vol 46 (5) ◽  
pp. 391-397 ◽  
Author(s):  
Phillip Levine ◽  
Kelly McDaniel ◽  
Heather Francis ◽  
Lindsey Kennedy ◽  
Gianfranco Alpini ◽  
...  
Keyword(s):  
Stem Cell ◽  
Liver Disease ◽  
Cell Therapy ◽  
Stem Cell Therapy ◽  
Alcoholic Liver Disease ◽  
Molecular Mechanisms

scholarly journals Cell Therapy for Liver Disease Using Bioimaging Rats

Cell Medicine ◽  
2017 ◽  
Vol 9 (1-2) ◽  
pp. 3-7 ◽  
Author(s):  
Junko Haga ◽  
Shin Enosawa ◽  
Eiji Kobayashi
Keyword(s):  
Bone Marrow ◽  
Liver Disease ◽  
Cell Therapy ◽  
Cell Transplantation ◽  
Liver Damage ◽  
Fluorescent Protein ◽  
Bone Marrow Cells ◽  
Damage Model ◽  
Chronic Liver ◽  
Chronic Liver Damage

Advances in stem cell research suggest that cell therapy is a potential alternative to liver transplantation. The use of individualized and minimally invasive cell therapy is desirable to avoid rejection and reduce patient burden. While allo-hepatocyte transplantation has been performed for metabolic hepatic disease, auto-bone marrow transplantation (BMT) has shifted toward mesenchymal stem cells (MSCs) transplantation for liver cirrhosis. In this article, an overview of cell transplantation research for liver disease is provided through our recent rat studies. We have developed various kinds of rat imaging models and have evaluated the effect of cell therapy for liver disease. Bone marrow cells (BMCs) of the Alb-DsRed2 rat were transplanted via the portal vein (PV) in acute and chronic liver damage models. The number of Alb-DsRed2+ albumin-producing cells increased, and the size of the cells increased in the chronic liver damage model as well as in the acute liver damage model. Luciferase transgenic (luc-Tg) rat hepatocytes were transplanted into the hepatectomized LEW rat via the PV. Luminescence intensity lasted for 2 months in the hepatectomized rat. BMCs obtained from green fluorescent protein (GFP) Tg rats were transplanted repeatedly via the PV using an implanted catheter with a port. Repeated BMT via the PV reduced the liver fibrosis. Adipocyte-derived MSCs from the luc-Tg rat were transplanted into the hepatectomized rat model via the PV after ischemic reperfusion. MSCs inhibited hepatocyte apoptosis and promoted liver regeneration. Transplanting the optimal number of cells by an effective and safe way is important for clinical application. Bioimaging rats are a powerful tool for cell transplantation research because it makes observation of the in vivo kinetics of transplanted cells possible. Cell transplantation research using bioimaging rats contributes greatly to evaluating effective methods of cell therapy.

Sign in / Sign up

Export Citation Format

Share Document